Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) used for the short-term relief of moderate to severe pain. The market for ketorolac is driven by the increasing prevalence of chronic pain conditions, such as arthritis and migraines, and the growing demand for effective pain management solutions. Additionally, the rise in surgical procedures and the need for post-operative pain management also contribute to the growth of the ketorolac market. However, the market growth may be hindered by the potential side effects of ketorolac, such as gastrointestinal bleeding and renal toxicity, which may limit its usage in some patients. The availability of alternative pain management options, such as opioids and acetaminophen, may also impact the demand for ketorolac. Overall, the ketorolac market is expected to continue growing due to the high demand for effective pain relief.
Key Competitors in the Ketorolac Industry:
1. Allergan plc
Allergan plc was founded in 1948 and is headquartered in Dublin, Ireland. The company operates in more than 100 countries and is focused on developing and commercializing innovative pharmaceuticals, biologics, and medical devices. In 2019, Allergan received approval from the US FDA for its supplemental new drug application (sNDA) for a new ophthalmic formulation of ketorolac tromethamine (Acular LS).
2. Deepcare Health Pvt Ltd
Deepcare Health Pvt Ltd is a healthcare technology company based in India, founded in 2018. The company is focused on providing personalized healthcare solutions using artificial intelligence and machine learning. Deepcare has developed a virtual assistant named 'Disha', which can prescribe medications, including ketorolac, based on patient symptoms.
3. Cadila Healthcare Limited
Cadila Healthcare Limited, also known as Zydus Cadila, is an Indian pharmaceutical company founded in 1952. The company operates in more than 50 countries and has a strong presence in the Indian pharmaceutical market. In 2020, Cadila received approval from the Indian regulatory authority for its generic version of ketorolac tromethamine injection.
4. Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1984. The company operates in more than 85 countries and is focused on developing and manufacturing a wide range of pharmaceuticals, including injectable and oral formulations. In 2019, Intas received approval from the US FDA for its abbreviated new drug application (ANDA) for ketorolac tromethamine injection.
5. Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited is an Indian pharmaceutical company founded in 1961. The company operates in more than 50 countries and is focused on developing and manufacturing generic pharmaceuticals. In 2011, Ranbaxy received approval from the US FDA for its ANDA for ketorolac tromethamine injection.
6. Omeros Corporation
Omeros Corporation is a biopharmaceutical company based in the US, founded in 1994. The company is focused on developing and commercializing small-molecule and protein therapeutics for inflammation, hematology, and CNS disorders. In 2020, Omeros received approval from the US FDA for its supplemental new drug application (sNDA) for ketorolac injection.
7. Nephron Pharmaceuticals Corporation
Nephron Pharmaceuticals Corporation is a US-based pharmaceutical company founded in 2007. The company is focused on developing and manufacturing generic inhalation solutions and injectable products. In 2018, Nephron received approval from the US FDA for its ANDA for ketorolac tromethamine injection.
8. Cycle Pharmaceuticals Ltd
Cycle Pharmaceuticals Ltd is a UK-based pharmaceutical company founded in 2012. The company is focused on developing and commercializing drugs for rare and orphan diseases. In 2021, Cycle received approval from the US FDA for its new drug application (NDA) for a novel sublingual ketorolac formulation.
9. Neon Laboratories Limited
Neon Laboratories Limited is an Indian pharmaceutical company founded in 1982. The company operates in more than 50 countries and is focused on developing and manufacturing generic and branded pharmaceuticals. In 2019, Neon received approval from the US FDA for its ANDA for ketorolac tromethamine injection.
*Definition- Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation in the body, particularly after surgery or injury. It works by blocking the production of certain natural substances that cause pain and swelling.
